$PTX Pernix Therapeutics INFO

New Post Public Reply Private Reply Replies (0) Message Board
MaxShockeR
$PTX Pernix Therapeutics INFO Watchlist


12% Treximet note interest payment due and premium to pay off drops from 106-103%:

Aug 1

(debt restructure news could come soon after)

After Aug 1, company saves 3% on the principal owed on Treximet notes, equating to around $6m in possible savings.
Then company should refund/refinance the existing 12% bonds by purchasing the outstanding bonds at 3% premium above
principal owed at time. After refunding old notes, issue new ones with lower interest rates (4-5%) and better terms.


New Jersey Annual Report Due (will have to report current directors, etc):

Due by July 31 (last day of the anniversary month of the entity's formation)

Filed on July 22nd last year.
(possibly followed up with PR confirming CEO to be Sedor)
(possible ammendedments to articles of incorporation in Maryland around same time)


PR confirming ER date/guidence on earnings:

~ July 28-29

(ER date has NOT been postponed since it was never confirmed yet. No reason to
think it would be delayed though. Aug 15 by absolute latest)


Q2 Earnings report:

~ Aug 4, 8am

2015 Q2 had $47m rev, street estimates for 2016 Q2 only $40.33m

Positive Trx uptrends for core 3 meds - confirmed by Matt Duffy in recorded call.
https://www.youtube.com/watch?v=cQ2GXim2OaA

With recent Q2 Trx data suggesting possibility of revenue approaching $47-50 mil in Q2,
there is high chance of meeting or beating Q2 2015 numbers AND exceeding current street
estimates by an estimated ~$6-10m. EPS probably still negative, but much improved over Q1.


Institutional quarterly holding report 13f-HR's due by:

2Q 2016 (June) August 15, 2016 (Monday)
3Q 2016 (September) November 14, 2016 (Monday)
4Q 2016 (December) February 14, 2017 (Tuesday)


FDA Final Action on Pernix Citizen Petition:

Estimated Tuesday, Aug 23rd. (180 days after submission)
Watch for comments closing on regulations.gov


Attending PAINweek 2016 (DD suggests presentation of zx007 clinical data):

sept 8th


gsk vs pernix: (relating to treximet deal)

arbitration hearing was held in April 2016
second hearing is scheduled for August 2016.
A decision by the arbitrators is expected in October 2016.

if lose will have to pay ~$15m more to GSK
if ruled in favor, PTX should get payment upwards of $50m from GSK


ZX007 (zohydro with intellitab) category 3 abuse potential study results / NDA submission:

sometime 2016 (probably after being presented at painweek in Sept)


Treximet Phase IV Trial on Workplace Migraine Treatment in progress (NCT01086358) :

Verified nearing full enrollment (59/60 patients) June 24 from recruiting doctor
Unknown when to expect news (possibly fall or winter)


Silenor OTC study completion:

mid Q3 (August)


Treximet alternate dose study completion:

mid Q3 (August)


Pernix vs Actavis/Alvogen: (related to generic zohydro entry)

- pernix sues both companies after submitting generic ndas (march)
- pernix ammends/strengthens complaint with 3 new Zohydro patents in May
- during pre-trial motions... actavis/alvogen argue zohydro patents are not enforceable (july)
- pernix repsonds with strong argument that actavis/alvogen claims on invalidity are frivolous
(no ruling on motion yet)
- pernix notifies court they will file preliminary injunction to extend blocking generic entry
until case settled (unless defendants agree voluntarily) (7/20)
- trial scheduled for December unless timeline changes



Final conversion of Silenor ot OTC market:

mid 2018 (evaluating go-it-alone launch vs partnership with OTC leader)

Following guide path laid out by meeting with FDA:
-Label comprehension study
-Transient Study – healthy subjects
-Actual use study

(news on studies unknown)


Silenor approved and launched in Canada with partner (Paladin), Approved in
Korea with partner (CJ) and potential for Japan is large (doxepin never
approved):

(Paladin also has right to launch in South America)

unknown when to expect news


Silenor possible combination/alternative isomers formulas:

Discovery Phase – IP Filed (unknown when to expect news)



Possible Buyout (minimum price target of $3.00):

Sometime after Aug 1 2016...

Probably after refinancnig debt, paying more of it down, couple positive Earnings reports,
patent litigations are over, and zx007 launched (maybe early 2017).
Read "Speculating on Pernix" for detailed article on buyout scenario:
http://seekingalpha.com/article/3979465-specu...erapeutics



Potential BUYOUT
http://www.insiderfinancial.com/pernix-therap...ut/116635/

DD source: humboldt

Pernix Therapeutics Holdings Inc. (PTXTQ) Stock Research Links

PTXTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 375

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading

Top 5 Most Recently Viewed Articles

Forecast Reveals Growth Surge in Healthcare IT by $199 Billion

Updated Category News Views 121

Growth Forecast for Healthcare IT Market The healthcare IT market is poised for substantial growth, projected to rise by USD 199.8 billion from 2024 to 2028. This growth is primarily fueled by an increasing emphasis on service quality and operational efficiency, alongside advancements in artificial intelligence (AI) technologies that are transforming healthcare practices....

Continue Reading
Revolutionizing Painting: Rust-Oleum's Low Odor Spray Paint

Updated Category News Views 197

Transform Your Painting Experience with Rust-Oleum For many, the smell of traditional spray paint can be quite off-putting, often making the creative process less enjoyable. Thankfully, Rust-Oleum has taken a bold step towards addressing this issue by introducing a product that fundamentally shifts the painting experience. Introducing Low Odor Premium Spray Paint...

Continue Reading
Banking Academy and Vantage Foundation Unite for Financial Growth

Updated Category News Views 116

Strategic Partnership Between Banking Academy and Vantage Foundation In an exciting development for financial education, the Banking Academy of Vietnam (BAV) and Vantage Foundation have formed a significant strategic partnership. This collaboration was marked by the signing of a Memorandum of Understanding (MoU) at the Banking Academy's headquarters, symbolizing a...

Continue Reading
Investor Alert: Dave Inc. Faces Class Action Investigation

Updated Category News Views 296

Understanding the Current Situation of Dave Inc. Recently, there has been a growing concern among shareholders of Dave Inc. (NASDAQ: DAVE) regarding potential misleading information disseminated by the company. This has prompted Rosen Law Firm, a respected advocate for investor rights, to initiate an investigation aimed at uncovering possible securities claims. As this...

Continue Reading
Exploring the Rise of GE Aerospace: Investors' Perspective

Updated Category News Views 289

Understanding GE Aerospace's Growth GE Aerospace has shown remarkable performance over recent years, outpacing the overall market significantly. For the last five years, it has delivered an astounding 38.48% return on an annualized basis, reflecting an impressive average annual return of 52.35%. This optimistic trend has contributed to its current market capitalization,...

Continue Reading